Roivant Sciences Ltd. Common Shares (ROIV)

About ROIV

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated wit…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

721

Website

roivant.com/

Fundamentals

1-day range

$34.69$37.13

Market cap

$24.08B

P/E (trailing)

—

P/E (forward)

-20.21

EPS (trailing)

$-0.39

Dividend yield

—

Beta

1.10

Avg. volume

5.52M

Forecasts

11 analyst ratings

Roivant Sciences Ltd. Common Shares Competitors

Chosen by industry and closest market cap.

• ROIV

  Roivant Sciences Ltd. Common Shares

  $34.71

  ▼ 7.64%
  Market cap $24.08BP/E —
  $11.85$37.97
• UTHR

  United Therapeutics Corporation Common Stock

  $515.57

  ▼ 2.34%
  Market cap $21.92BP/E 17.03
  $302.19$609.35
• INSM

  Insmed Incorporated Common Stock

  $118.52

  ▼ 2.36%
  Market cap $21.34BP/E —
  $90.39$212.75
• VTRS

  Viatris Inc. Common Stock

  $16.34

  ▼ 3.26%
  Market cap $20.53BP/E —
  $9.43$18.39
• ZTS

  Zoetis Inc. Class A Common Stock

  $77.36

  ▲ 3.12%
  Market cap $32.32BP/E 11.54
  $71$156.49
• JAZZ

  Jazz Pharmaceuticals plc Common Stock (Ireland)

  $244.6

  ▼ 2.59%
  Market cap $15.80BP/E 16.97
  $123.88$266.38
• BBIO

  BridgeBio Pharma Inc. Common Stock

  $76.62

  ▼ 2.62%
  Market cap $15.65BP/E —
  $48.78$93.42

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $41 Price Target
  benzinga · 8/28/2026